Little is known as to how the nuclear oncogenes v-erbA and p135
Introduction
Both the v-erbA oncogene, carried by the Avian Erythroblastosis Virus (AEV), for a review, see and the p135 gag-myb-ets oncogene carried by the E26 virus (Moscovici et al., 1983; Radke et al., 1982) act through the blockade of speci®c dierentiation programs. Those two oncoproteins are derived by recombination within the viral genome of cellular genes encoding transcriptions factors and are considered to transform cells through their ability to aect the expression of genes normally regulated by their cellular counterparts (respectively c-erbAa, c-Myb and c-Ets-1). The identi®cation of the relevant target genes therefore represent a mandatory step in our understanding of the function of those proteins.
To date, only three p135 gag-myb-ets -target genes (mim-1, rem-1 and bcl-2; Ness et al., 1989; Kraut et al., 1995; Frampton et al., 1996) and two v-erbA target genes (carbonic anhydrase II (CAII) and BandIII; Pain et al., 1990; Zenke et al., 1988) have been described. Nevertheless, functional studies have clearly demonstrated that those genes are either non-relevant (as is the case for BandIII; Peters et al., 1996; Inaba et al., 1996) or not sucient to account for the differentiation-blocking ability of the oncoproteins (as is the case for CAII (Fuerstenberg et al., 1992) , rem1 (Kraut et al., 1995) , and bcl-2 (Frampton et al., 1996) .
One putative candidate for the role of target gene for those oncoproteins is the RARb gene for a number of reasons:
First, we have demonstrated the involvement of both RARs and T3Rs (trii odothyronine (T3) receptors) in the control of the commitment process that leads from a self-renewing BFU-E to a committed CFU-E that either dies by apoptosis or terminally dierentiates, depending on the hormonal factors present (Gandrillon et al., 1994) .
Second, it had been suggested that the ability of the v-erbA oncogene to interfere with retinoids-controlled pathways was essential for its transforming ability (Sharif and Privalsky, 1991; Schroeder et al., 1992; Gandrillon et al., 1994) .
Third, the RARb gene has been shown to be induced by retinoic acid addition in normal erythrocytic progenitor cells (Gandrillon et al., 1994) .
Fourth, both we (Rascle et al., 1996) and others (Sande et al., 1993) have described that no such induction was detected in, respectively, E26-and AEV-transformed cell lines.
Taken together, all those data point toward the RARb gene as a promising target gene for the v-erbA and the p135 gag-myb-ets oncoproteins. At the molecular level, the studies addressing the functional interactions between the v-erbA oncogene and a retinoic acid response element (RARE) have generated con¯icting results. The inhibition seems to depend upon the structure of the RARE and the nature of the host cells. The v-erbA oncoprotein inhibits RA-induced transcription from the PAL-0 but not from the DR-2 response element (Hermann et al., 1993) . It does not inhibit DR-5 RARE in P19, COS-7 and MCF-7 cells (Barettino et al., 1993; Sharif and Privalsky, 1991) in contrast to HeLa cells (Rascle et al., 1996) . In CV-1 cells the DR-5 RARE composed of two repeats of the AGGTCA motif is eciently repressed by v-erbA in contrast to the imperfect DR-5 made of the AGTTCA and GGTTCA motifs which is in agreement with the binding eciency of the oncoprotein to these elements . In HeLa cells transcription from the imperfect DR-5 is repressed by v-erbA like the whole promoter of the RARb gene which contains this speci®c RARE (Rascle et al., 1996) . In some cases, a transcriptional activation by v-erbA has been reported (Sharif and Privalsky, 1992) .
Most of the discordance can be attributed to the use of dierent cell types, none of which is fully relevant toward the v-erbA transforming ability, and to various response element sequences, none of which is of avian origin nor correspond to the natural targets of the oncoprotein. Whether the chicken RARb gene promoter contains a perfect DR-5 RARE or not might very well in¯uence the ability of the v-erbA oncogene to inhibit its expression in chicken cells.
We therefore decided to investigate that issue by using the relevant target cells (i.e. freshly transformed chicken erythrocytic progenitor cells) without altering their normal receptor content.
In the present work, we have explored some characteristics of the RARb gene response in erythrocytic progenitor cells. We then show that this gene is not a target gene for the v-erbA nor the p135 gag-myb-ets oncogenes, although the expression of one of those oncoproteins is sucient to completely abolish the cellular responses to retinoids. Those results point toward dierent roles for the various retinoid receptor isoforms. We therefore explored the respective roles of the dierent isoforms in the control of the commitment inducing ability of retinoids.
Results

The expression of the RARb gene is induced in erythrocytic progenitor cells by retinoids addition
In order to isolate genes that are involved in the control of the commitment of early self-renewing erythrocytic progenitors into maturing erythroblasts, we have screened the expression of a number of genes by RT ± PCR in AEV-H progenitor cells treated for 18 h with various hormones that are known to induce either the commitment (all-trans RA, 9-cis RA and L-T3) or to induce the self-renewal of erythrocytic progenitor cells (Estradiol; E2) or without known activity (Vitamin D3; VitD3).
We used AEV-H-transformed cells instead of normal erythrocytic progenitor cells because these cells could be much more easily grown on large scale cultures. Although we could not formally exclude that the expression level of some genes might be altered by the v-erbB gene product we nevertheless considered that they would provide a convenient model to identify genes induced by hormonal stimulation. Furthermore, some of the key results we have obtained on AEV-H progenitor cells were reproduced on normal noninfected chicken progenitor cells and found to be very similar, if not identical.
Most of the tested genes were found to be expressed in AEV-H progenitor cells and no variation under hormonal in¯uence could be detected in their expression (data not shown). This class of genes include genes encoding nuclear hormone receptors (RARa, RARg, T3Ra, VD3R, Reva, Revb, Estrogen Receptor), membrane-spanning receptors (c-kit, Transferrin Receptor, Epidermal Growth Factor Receptor, Insulin Receptor, Insulin-like Growth Factor Receptor), a src family-related protein tyrosine kinase (c-fyn), transcription factors (c-rel and GATA-1), a differentiation-associated enzyme (Carbonic AnhydraseII; CAII) and the apoptosis-inhibiting protein bcl-2. The lack of detectable activation of the CAII gene is a clear indication of the limitations due to the sensitivity of the technique. The expression of this gene has indeed been shown by Northern blot analysis to be only slightly induced by the addition of T3 in the absence of erythropoietin (Pain et al., 1990) .
The expression of two of the tested genes (c-erbA b and RXRg) could not be detected in any condition in those progenitor cells whereas they were easily detected in, respectively, brain and CEFs samples used as positive controls (data not shown).
Finally, of all the tested genes, only the RARb gene expression was found to be strongly induced by retinoids addition (either all-trans or 9-cis retinoic acid) starting from undetectable levels in untreated cells ( Figure 1a ). In this respect the AEV-H-progenitor cells behave exactly like normal TECs that have previously been shown to induce the RARb gene expression in response to retinoids addition (Gandrillon et al., 1994) .
The induction of the RARb gene is a direct and speci®c eect of retinoids addition
We then analysed the characteristics of the RARb gene induction. We ®rst demonstrated that this induction was occurring both in the absence and in the presence of anisomycin (Lewis and Mathews, 1980) , a very ecient inhibitor of protein synthesis (Figure 1b ). This demonstrates that the induction of the RARb gene is a direct eect that does not require ongoing protein synthesis.
We then analysed the kinetics of the RARb gene response, in the absence or presence of another inhibitor of protein synthesis, cycloheximide (CHX; Figure 1c ). In the absence of CHX, the RARb gene expression was hardly detectable 4 h after retinoids addition and became clearly detectable after a 24 h treatment. All of the subsequent experiments were then performed after an 18 h long treatment. In the presence of CHX, a slight stabilisation of the RARb mRNA was detected 4 h after retinoids addition that disappeared for longer treatment times. This stabilisation might be due to the inhibition of synthesis of short-lived proteins that destabilize the RARb mRNA.
We performed a dose-response experiment ( Figure  1d ) that indicates that the addition of low doses of alltrans retinoic acid (10 nM) was sucient to induce a clearly detected RARb gene response, thereby demonstrating the physiological relevance of the observed phenomenon.
The activation of the RARa isoform is responsible for the observed RARb gene response
We then explored which isoform(s) of the retinoids receptors were responsible for the observed response. This was made possible by the recent description of ligands that are speci®c for a given isoform(s). The following compounds were used: the RARa-speci®c agonists Ro40 and CD336, the RARb-speci®c agonist Ro48, the RARg-speci®c agonist CD437, the RXRs (all isoforms)-speci®c agonist Ro25 and the RARaspeci®c antagonist Ro41.
When added at 10 nM, a concentration where no cross-activation does occur (Roy et al., 1995; Reichert et al., 1993) , none of the ligands that speci®cally activate the RARb (Ro48), RARg (CD437), nor all isoforms of the RXRs (Ro25) were able to induce any detectable RARb gene expression (Figure 2a) .
Only the two ligands that speci®cally activate the RARa isoform (Ro40 and CD336) proved able to induce such a detectable RARb gene induction ( Figure  2a) . It is to be noted that those two ligands share very similar (if not identical) chemical structure that they also share with the AM580 RARa-selective compound (Gianni et al., 1996; Martin et al., 1992; M Klaus, personal communication) . It is thus not surprising that they behave similarly.
These results tend to indicate that the speci®c activation of the RARa isoform (the mRNA of which is expressed in AEV-H-progenitor cells (not shown)) is sucient to induce the RARb gene response. This was further con®rmed with the use of Ro41, a RARaspeci®c antagonistic ligand (Apfel et al., 1992; Rogers, 1996; Mills et al., 1996) . The addition of such an antagonist, at 10 76 M, is sucient to completely abolish the RARb gene response induced by the addition of 10 78 M all-trans RA (Figure 2b ). The functional activation of the RARa isoform therefore represents a necessary and sucient event to explain the induction of the RARb gene by retinoids addition.
The activation of the RARa isoform is also sucient to induce a detectable RARb gene response in normal erythrocytic progenitors cells (Figure 2c ) thereby demonstrating that this was not due to the expression of the v-erbB oncogene in AEV-H-progenitor cells.
We then performed a dose-response experiment ( Figure 2d ) that indicates that the RARa-speci®c ligand CD336 was active at up to 1 nM, a lower dose than required to detect the induction mediated by alltrans RA. Such an eect can be explained by the trapping of part of the all-trans RA molecules by the other RAR and RXR isoforms in contrast to the CD336 molecules which are all available for RARa activation. Dierences in the stability of all-trans RA and synthetic compounds (which are known to be chemically and light stable; U Reichert, personal communication) could also play a role.
We then explored whether, once the RARb gene is induced, the RARb isoform that is synthesised becomes able to self-regulate its own gene expression. AEV-H-progenitor cells were treated for 24 h with an RARa-activating ligand, in order to induce RARb gene expression, and then grown for another 24 h either in the presence of an RARa-activating ligand or in the presence of an RARb-activating ligand ( Figure  2e ). When cells were grown continuously in the presence of the RARa-activating ligand, a sustained RARb gene expression was detected. By contrast, in the cells that were shifted to a medium containing an RARb-activating ligand, no RARb gene expression was detected. This demonstrates that the RARb isoform is unable to self-activate its own gene expression and that the continuous activation of the RARa isoform is required to maintain a constant RARb gene expression.
It has been well established in a number of model systems that retinoids action is frequently mediated via the formation and activation of heterodimers between one member of the RAR family and one member of the RXR family (Dey et al., 1994) . The formation of such heterodimers can be functionally assessed by the cooperation of RAR-speci®c ligands with RXR-speci®c ligands (Roy et al., 1995) .
We therefore examined the RARb gene expression in AEV-H-progenitor cells treated with sub optimal concentrations of Ro40 (10 710 M) in the presence or absence of 10 78 M of the RXRs-activating ligand Ro25 (Figure 2f ). No RARb gene expression was detected when either compound was added alone, but also when both compounds were added together. Similar results were obtained with 10 79 M Ro40 (not shown). Those results show that no functional cooperation can be detected in this assay. This absence of cooperation is in contrast with the synergy that we observed on the growth inhibition mediated by retinoids.
The two nuclear oncogenes v-erbA and p135 gag-myb-ets are not sucient to inhibit the RARb gene induction.
The RARb gene is strongly induced by retinoids addition (either all-trans or 9-cis retinoic acid) starting from undetectable levels in untreated cells. On the other side, no RARb gene expression was detected after all-trans-retinoic acid treatment in AEV-transformed cell lines (Sande et al., 1993) . This gene therefore represents a putative target gene for the verbA oncogene.
We ®rst veri®ed that no RARb gene expression was induced by all-trans RA treatment of another AEVtransformed cell line, the HD4 cell line (Figure 3a , left panels). Nevertheless, to our surprise, the situation was completely dierent when assessed on primary 78 M of the RARaspeci®c agonist Ro40 and for another 24 h in the presence of 10 78 M of the RARa-speci®c agonist Ro40 or in the presence of 10 78 M of the RARb-speci®c agonist Ro48. The expression level of the GAPDH and RARb genes was then determined by RT ± PCR. (f) AEV-H progenitor cells were treated for 18 h in the presence of the indicated concentrations of the RARa-speci®c agonist Ro40 and of the RARg-speci®c agonist Ro25 either alone or in combination. The expression level of the GAPDH and RARb genes was then determined by RT ± PCR transformed cells (i.e. bone marrow cells freshly transformed with an AEV virus). Those cells did respond to all-trans RA treatment by a clear increase in the RARb gene expression levels ( Figure 3a , middle panels). We veri®ed that this was not due to some rare integration events by assessing three dierent clones that did all respond to the RA treatment. We also veri®ed that these cells did express the v-erbA oncogene at a detectable level (Figure 3a) . We have further veri®ed that this signal was not due to a subpopulation of cells infected with a viral variant that had deleted all or part of the v-erbA sequence (not shown).
In order to assess whether the observed behaviour of the HD4 cell line was due to some mutations in the AEV genome that these cells express, viral particles from HD4 cultures were ®ltered and used to infect fresh bone marrow cells. Those freshly transformed cells did respond to all-trans RA treatment (Figure 3a , right panels). This indicates that the defect leading to the absence of RA response in HD4 cells is due to some non-viral component.
We then explored the characteristics of the RARb gene induction in v-erbA-expressing cells. We found that those cells behaved very similarly to AEV-Hprogenitor cells both for their dose-response ( Figure  3b ) and for the involvement of the RARa isoform in the response (Figure 3c ).
In conclusion, the expression of the v-erbA oncogene, per se, is not sucient to signi®cantly modify the RARb gene induction.
We had previously shown that no RARb gene expression was detected after all-trans-retinoic acid treatment in established cell lines transformed with E26, a retrovirus that expresses the p135 gag-myb-ets nuclear oncogene (Rascle et al., 1996) . We therefore decided to verify if the expression of that oncogene would be sucient to block the RARb gene induction. The situation proved to be identical to the one observed previously with the v-erbA oncogene: no RARb gene induction was detected in an established cell line (HD57-E) but primary E26-transformed cells did respond to all-trans RA treatment by a clear increase in the RARb gene expression levels ( Figure 3d ) although they all clearly expressed the p135 gag-myb-etsencoding mRNA. We have veri®ed that similar results could be obtained using E26-transformed cells selected for the expression of the erythrocytic-speci®c JS4 antigen (Schmidt et al., 1986) , thereby demonstrating that this was not due to the presence of myeloid E26-transformed cells (data not shown).
Together our results suggest that the repression of the RARb response is not a prerequisite for primary transformation of erythrocytic progenitor cells and that the RARb gene is not a direct target of neither the verbA nor the p135 gag-myb-ets oncogenes.
The loss of RARb gene response is not a prerequisite for cellular immortalization
We then explored the possibility that the repression of the RARb response was correlated with the immortalization process. For this we investigated the RARb response in two dierent cell lines:
(1) ABTCE cells, a chicken erythrocytic cell line transformed by AEV and the SV40 large T antigen that was generated in our laboratory. (Figure 4b ). It is interesting to note that the retinoic acid addition onto normal chicken macrophages was reported to induce a strong growth stimulation (Woods et al., 1995) , quite dierent from the commitment-inducing response of erythrocytic progenitor cells. Nevertheless, in both cases, the RARb gene was induced.
Together our results rule out the possibility that the loss of RARb gene response might be a prerequisite for cellular immortalization.
The activation of the RARa isoform is sucient to induce a cellular response on growth and dierentiation of erythroid progenitor cells
Taken together, our results show that:
(1) the activation of the RARa isoform is responsible for the induction of the RARb gene and that:
(2) the expression of either the v-erbA or the p135 gag-myb-ets oncogene does not block this response. Those two results are in apparent contradiction with a number of previous studies by our and other laboratories that demonstrated the existence of a negative interference between nuclear hormone receptors and one of those oncogenes. This therefore raises the question as to whether the activation of the RARa isoform is also involved in the physiological response of the cells to retinoids or is nothing but a side eect controlling the RARb induction without inducing any noticeable cellular response.
We therefore assessed the cellular response to the dierent isoform-speci®c ligands. For this we took advantage of the previously described growth inhibitory eect, related to the commitment-inducing ability of retinoic acid (Gandrillon et al., 1994) . We ®rst veri®ed that the addition of increasing doses of alltrans retinoic acid on AEV-H progenitor cells ( Figure  5a ) or on normal erythrocytic progenitor cells ( Figure  5b ) induced a clear reduction in the cell number assessed 48 h after the ligand addition. As previously observed (Gandrillon et al., 1994) , we veri®ed in that case by FACS analysis that this cell number reduction was accompanied by an increase in the frequency of apoptotic cells appearing as a sub-G1 peak (not shown). Normal progenitor cells were sensitive to lower all-trans retinoic acid doses, as expected from the growth-stimulating eect of the v-erbB oncogene that could partly counteract the all-trans retinoic acid eects in AEV-H cells.
The addition of the RARa-activating ligand Ro40 had very similar eects to all-trans retinoic acid whether acting on AEV-H progenitor cells ( Figure  5c ) or on normal progenitor cells (Figure 5d ). The dose response curves to all-trans retinoic acid and to Ro40 were very similar for a given cell type, thereby suggesting that most, if not all, of the all-trans retinoic acid eect can be explained by the activation of the RARa isoform. We have veri®ed in that case that the XTT value was an accurate re¯ection of the cell number by demonstrating that identical cell numbers, whether treated by Ro40 or not, displayed similar XTT activity (not shown).
We further explored the ability of the other isoformspeci®c ligands to induce a growth inhibitory eect on AEV-H progenitor cells. Neither Ro48 (Figure 5e ) nor CD437 (Figure 5f ), that activate respectively the RARb and the RARg isoforms, were able to induce any signi®cant reduction in the growth of AEV-H progenitor cells. A similar lack of eect was noticed on normal progenitor cells (not shown).
Only a small growth inhibition, at the highest dosage, was noted when AEV-H progenitor cells were (Figure 5g ). This inhibition might result from a cooperative eect between high doses of Ro25 and the endogenous concentrations of retinoic acid.
The combination of 100 nM Ro25 with increasing doses of the RARa-activating ligand Ro40 resulted in a synergistic eect on the growth reduction of AEV-H progenitor cells (Figure 5h ). This suggests that at least some of the genes that are involved in that growthreduction, apoptosis-inducing process are under the control of RAR/RXR heterodimers.
We then tested the eect of RARa activation on the dierentiation process. For this, T2ECs were induced to dierentiate in conditions allowing only a low dierentiation level (3 days in the presence of Epo/Ins and in the presence of growth factors). In those conditions, the addition of Ro40 at 10 78 M induced a very clear increase in the percentage of dierentiated cells (Figure 6a) . None of the other tested molecules were able to elicit such a stimulation. This therefore demonstrates that the activation of the RARa isoform is sucient to stimulate the dierentiation of erythroid progenitor cells, as previously demonstrated for alltrans RA (Schroeder et al., 1992) . (Control) or presence of 10 nM of the RARa-speci®c agonist Ro40, the RARb-speci®c agonist Ro48, the RARg-speci®c agonists CD437 or the RXRs (all isoforms)-speci®c agonist Ro25. T2ECs were induced to dierentiate in the presence of 0.5 U/ml erythropoietin and 10 ng/ml insulin (Epo/Ins) and in the presence of growth factors for 3 days and the percentage of benzidinepositive cells was determined and is expressed as a percentage of the control mock-treated cells. Shown is the mean +s.d. observed in four independent determinations (Control and Ro40) or in one determination performed in duplicates (Ro48, CD437 and Ro25). **:P=0.1% by student's t-test analysis. All other dierences were not signi®cant. (b) Dierentiation level observed in the absence (Control) or presence of a neutralizing anti-T3 antibody (a-T3), of 2.10 76 M of the RARa-speci®c antagonist (Ro41) or a combination thereof. T2ECs were grown for 24 h in the absence or presence of a-T3 and Ro41 and induced to dierentiate, in the absence or presence of a-T3 and Ro41, by the addition of 15% ACS and in the absence of growth factors for 6 days. The percentage of benzidine-positive cells was determined and is expressed as a percentage of the control mock-treated cells. Shown is the mean +s.d. observed in three independent determinations. **:P=0.1% by student's t-test analysis. All other dierences were not signi®cant In order to assess the necessity of the RARa activation in the dierentiation process, we then tried to inhibit this process. T2ECs were induced to dierentiate in conditions allowing a high differentiation level (6 days in the presence of ACS and in the absence of growth factors). We have previously shown that the presence of endogenous sources of ATRA and L-T3 in the medium is both necessary and sucient to permit a noticeable level of dierentiation in the absence of further additions (Gandrillon et al., 1994) . In those conditions, although the addition of either a neutralizing anti-T3 antibody or of a RARa-speci®c antagonist (Ro41) had no eect, the simultaneous addition of both compounds severely reduced the dierentiation ability of the T2ECs (Figure 6b ). This result is in good accordance with previously published work demonstrating that T3 and RA can substitute for each other in inducing dierentiation (Gandrillon et al., 1994) . This further demonstrates that the activation of the RARa isoform is necessary for the differentiation process.
In conclusion, the activation of the RARa isoform seems to suce to explain most, if not all, of the cellular activity of all-trans retinoic acid on erythrocytic progenitor cells and therefore represents a key event in this process.
Either the v-erbA or the p135 gag-myb-ets nuclear oncogene is sucient to inhibit the retinoids-induced cellular response
We ®nally investigated how the expression of the verbA or of the p135 gag-myb-ets oncogene would interfere with the cellular response mediated by the dierent retinoic acid receptors isoforms.
Bone marrow cells were freshly transformed by AEV infection and grown for 48 h in the presence of increasing concentrations of isoforms-speci®c ligands shown above to inhibit the growth of AEV-H progenitor cells (Figure 7a ± d) . In every instance, the AEV-transformed cells proved to be completely refractory to the growth inhibitory action of either all-trans retinoic acid (Figure 7a ), Ro40 (Figure 7b ), Ro25 (Figure 7c ) or even to the combination of Ro25 and Ro40 (Figure 7d) .
Identical results were obtained on bone marrow cells freshly transformed by E26 infection (Figure 7e ± 8h) . These cells also proved to be completely refractory to the growth inhibitory action of any tested compound, in accordance with previously published results (Rascle et al., 1996) .
Altogether, our results con®rm that cells expressing either the v-erbA or the p135 gag-myb-ets oncogene become completely insensitive, in terms of growth-inhibition, to the addition of retinoids, whether all-trans retinoic acid or any isoform-speci®c ligand alone or in combination, while at the same time, those cells continue to respond to the addition of retinoids in terms of RARb gene induction. 
Discussion
In the present work, we have established that the RARb gene induction in chicken erythrocytic progenitor cells is a direct and speci®c eect of retinoids addition. Although we have not formally established that this induction occurs through a bona ®de transcriptional activation, such a mechanism has been documented in other cell types (Dey et al., 1994; Spanjaard et al., 1995 and references therein) and is supported by the absence of protein synthesis requirement in our cells. The transcriptional activation therefore represents the most likely mechanism for RARb gene induction and awaits cloning of the chicken RARb promoter for further studies.
We have shown that the RARb gene induction is under the exclusive control of the RARa isoform without any detectable redundancy between the three RAR isoforms, in contrast to what has been described in other model systems (Rogers, 1996; Roy et al., 1995) . Similarly, no redundancy was detected in the cellular eects of the retinoids. These results question the validity of the results obtained in non-relevant cell lines experimentally overexpressing massive amounts of receptor. Based on those studies, one would have predicted that the RARg and, once it is present, the RARb isoforms would be able to bind to and activate the RARb gene promoter, which is clearly not the case. This is in good accordance with in vivo studies using RARb-speci®c ligands where, to our knowledge, no functional auto-activation has been reported for the RARb gene.
In most, if not all, of the models studied, the RARb gene has been shown to be regulated by the formation of RAR-RXR heterodimers (Dey et al., 1994; Xiao et al., 1995; Spanjaard et al., 1995; Chen et al., 1996; Roy et al., 1995) . Nevertheless, those heterodimers have been shown to be sensitive to the addition of RXRspeci®c ligands (Roy et al., 1995) or not (Xiao et al., 1995) depending on the cell type studied. We were unable to detect any such cooperation upon the RARb gene expression level in our cells, although the presence and functionality of RXRs can be deduced from the clear synergism between RAR-speci®c and RXRspeci®c ligands in the growth inhibition test. This suggests that in chicken erythrocytic progenitor cells, the molecular mechanisms regulating the RARb gene and the genes involved in the commitment process might be dierent.
The possibility that the RARb gene might represent a target for the v-erbA or the p135 gag-myb-ets oncogene arose from con¯icting data (see Introduction). We therefore decided to reinvestigate this issue by using relevant target cells without altering their normal receptor content. Our results clearly establish that erythrocytic progenitor cells freshly transformed by the expression of either the v-erbA or the p135 gag-myb-ets oncogene, are still able to respond to retinoids by an increase in their RARb gene expression level. Furthermore, the parameters tested (dose-response and isoform speci®city) were identical between cells expressing v-erbA or not.
The loss of RARb gene response that was previously noted (Sande et al., 1993; Rascle et al., 1996) therefore represents a late event that occurred in some but not all of the tested cell lines. The signi®cance of that loss is still obscure. It does not relate to the immortalization process. It has recently been suggested that the loss of RARb gene response might be correlated with the acquisition of a tumorigenic potential (Jing et al., 1996) . This is a possibility that has yet to be explored in our system. This question relates to the function of the RARb gene product in our cells.
One important feature of the erythrocytic progenitor cells freshly transformed by the expression of either the v-erbA or the p135 gag-myb-ets oncogene is that, although they can still respond in terms of RARb gene induction, they have become completely insensitive to the presence of retinoids in their environment in terms of growth inhibition. Our results therefore favour a mechanism of action through which either the v-erbA or the p135 gag-myb-ets oncogene are able to discriminate between dierent retinoid-mediated responses and to block only those responses which are relevant toward the commitment-inducing ability of retinoids. This is highly reminiscent of the situation observed in U937 cells where it has been suggested that the addition of Vitamin D3 selectively inhibited the retinoid-induced dierentiation program but not the RARE-mediated signal (Botling et al., 1996) . This raised the intriguing possibility that the Vitamin D3 might inhibit the terminal dierentiation of erythrocytic progenitor cells.
We proposed a model (Figure 8 ) in which the process of commitment to dierentiation or apoptosis is not only under the overall control of the RARa isoform, but under the control of only a subset of the RARa-mediated responses. At least two groups of genes can be distinguished:
(1) a ®rst group, exempli®ed by the RARb gene the activation of which would be neither stimulated by the addition of an RXR-speci®c ligand nor repressed by the expression of the v-erbA or the p135 gag-myb-ets oncogene. One intriguing question concerns the function of those genes. We have shown that the retinoic acid addition induces RARb gene expression in normal chicken macrophages (which are induced to proliferate by retinoids; Woods et al., 1995) , as well as in erythrocyte progenitor cells (which are induced to dierentiate by retinoids). This suggests that either the function of the RARb gene product is highly cell-speci®c or that it is unrelated to the proliferation/dierentiation decision-making process.
(2) a second group, the identity of which still has to be established. The activation of those genes would be both stimulated by the addition of an RXRspeci®c ligand and repressed by the expression of the v-erbA or the p135 gag-myb-ets oncogene. The activation of this gene subset would be directly involved in the commitment-inducing ability of retinoids. Part of this subset could also be regulated by ligand-activated T3R, thereby explaining why T3 and RA can substitute for each other in inducing dierentiation. Taken together, our results are in good accordance with the studies that have established a crucial role for the RXRs isoforms in the transcriptional repression by v-erbA (Hermann et al., 1993; Barettino et al., 1993; Chen and Privalsky, 1993; Cassar-Malek et al., 1997) . They nevertheless contrast with the involvement of RXR/RXR homodimers in the growth-inhibition induced by retinoids in human erythrocytic progenitor cells (Rusten et al., 1996) .
Finally, one might envision that such a wiring is speci®c for the last stages of the erythrocytic dierentiation sequence. The existence of a myeloid cell line expressing both the v-erbA and the p135 gag-myb-ets oncogene and that is fully RA-sensitive in terms of dierentiation ability (Al Moustafa et al., 1994) , could be explained by a dierent set of interactions operative in the myeloid lineage (for example, involvement of the group 1 type gene in the dierentiation process).
In summary, our data eliminates the RARb gene from the list of the putative relevant targets for the verbA and the p135 gag-myb-ets oncogenes and allows a better determination of the criteria that a gene will have to ful®l to stay on the list: it will have to be induced by the addition of a RARa-speci®c ligand, to be sensitive to the concomitant addition of a RARaspeci®c ligand and of a RXR-speci®c ligand, possibly to be sensitive to the addition of T3 and to be repressed by v-erbA or p135 gag-myb-ets oncogenes in freshly transformed bone marrow cells.
In conclusion, our data contribute to the dissection of multiple regulatory pathways for the regulation by retinoids of the commitment to apoptosis and dierentiation in early chicken erythrocytic progenitor cells. They will allow now to better investigate the molecular mechanisms of action of the v-erbA and p135 gag-myb-ets oncogenes in the process of the leukemic transformation.
Materials and methods
Cells
Dierent sources of erythrocytic progenitors were used. For a discussion on the respective merits of the dierent types of progenitors, see Schroeder et al., 1992. Most of the studies were performed using bone marrow cells from 19 days old SPAFAS embryos that were infected as previously described (Gandrillon et al., 1989) with AEV-H (Avian Erythroblastosis Virus-H), a retrovirus carrying the verbB oncogene as the sole oncogene. This virus induces a strong hyper-proliferation of progenitor cells that retain their ability to dierentiate (Yamamoto et al., 1983) . Those cells will be referred to as`AEV-H progenitor cells'. They were grown in a medium consisting of a-modi®cation of Eagle's medium (a-MEM) containing 10% foetal bovine serum (FBS; Gibco BRL); 1% normal chicken serum (NCS; Gibco BRL); 10 74 M betamercaptoethanol (Sigma) and 1% of a 1006antibiotics solution (penicillin plus streptomycin; Flow Laboratories).
Some of the key results obtained on AEV-H progenitor cells were reproduced on normal non-infected chicken progenitor cells grown in liquid culture in a medium based on published media (Schroeder et al., 1993 ) and the precise description of which will be made elsewhere (Gandrillon and Samarut, manuscript in preparation) . Those cells will be referred to as`T2ECs'. By all parameters tested, those cells are equivalent to the previously described TECs (Pain et al., 1991) , except that they can be grown in liquid culture conditions. AEV (Graf and Beug, 1978) and E26 (Leprince et al., 1983) primary transformed cells were infected as described and grown in the same medium as AEV-H-progenitor cells.
The HD4 cell line is a chicken erythroblast cell line composed of cells which are blocked in their dierentiation program at the CFU-E stage by the AEV and were grown in the same medium as AEV-H-progenitor cells.
The HD57-E cell line was derived from the multipotent HD57 cell line, a gift of Dr T Graf (EMBL; Heidelberg). These cells were grown in a modi®ed`blastoderm medium' (Metz and Graf, 1991) in the absence of insulin and with a replacement of conalbumin with bovine serum albumin (BSA; Boehringer Mannheim).
The ABTCE cell line, a gift of Dr C Cleuziat (ENS de Lyon), is a chicken erythroblast cell line transformed by AEV and the SV40 largeT antigen. Those cells were grown in a-MEM containing 10% FBS, 5% NCS; 5% BSA; 10 74 M betamercaptoethanol and 1% of a 1006antibiotics solution.
Normal chicken macrophages were a kindly provided by S Ory and P Boissy (ENS de Lyon) and were grown as previously described (Woods et al., 1995) .
The HD11 cell line is a chicken macrophage cell line transformed by MC29 (Beug et al., 1979) . Those cells were grown in BT88 medium supplemented with 10% tryptose phosphate broth, 5% FBS and 5% NCS.
Chemicals
All-trans Retinoic acid (ATRA; Sigma) and 9-cis RA were prepared as 10 73 M solutions in ethanol and subsequently diluted in alpha MEM.
3,3',5-triiodo-L-thyronine (T3; Sigma) was prepared as a 10 72 M solution in 0.1 N NaOH and subsequently diluted in alpha MEM.
The vitamin D3 (VitD3; 1,25-(OH) 2 D 3 ) was a gift of Dr M Uskokovic (Homann-La Roche Ltd; Nutley, NJ). It was prepared as a 10 73 M solution in ethanol and subsequently diluted in alpha MEM.
b-Estradiol (E2; Sigma) was prepared as a 10 72 M solution in ethanol and subsequently diluted in alpha MEM.
The isoform-speci®c ligands Ro40-6055 (Apfel et al., 1992) , Ro25-7386, Ro41-5253 (Apfel et al., 1992) and Ro48-2249 (Geisen et al., 1997) (abbreviated respectively Ro40, Ro25, Ro41 and Ro48) were a gift of Dr M Klaus (Homann-La Roche Ltd; Basel). The binding and activation data for the compound Ro25-7386 were provided as a personal communication from Dr C Apfel and Dr M Klaus and are available on request from ogandril@cri.ens-lyon.fr.
The isoforms-speci®c ligands CD336 (=Am 580; Martin et al., 1992) and CD437 (Reichert et al., 1993) were kindly provided by Dr U Reichert (CIRD; Sophia Antipolis). They were resuspended as 5.10 72 M stock solution in DMSO and subsequently diluted in DMSO.
Anisomycin (Sigma) was dissolved in chloroform at a 100 nM concentration.
Cycloheximide (CHX; Sigma) was dissolved in water as a 15 mg/ml stock solution.
The neutralizing anti-T3 monoclonal antibody was purchased from Biogenesis.
Reverse-transcription plus polymerase chain reaction (RT ± PCR) analysis
Total RNAs were isolated using TRIZOL reagent (Gibco BRL). One microgram of isolated RNA was reversetranscribed for 45 min at 378C using random primers with 200 units of Mo-MuLV reverse-transcriptase (Gibco BRL) as previously described (Gandrillon et al., 1994) . The reverse-transcription reaction was terminated by boiling the resulting cDNAs for 5 min. An aliquot of the reverse-transcription mixture was then ampli®ed. For semi-quanti®cation purposes, dilutions of the RT mixture were used in pilot experiments in order to estimate the region of template amounts that would produce a plateau eect. All further experiments were carried outside the plateau region, using such conditions that a decrease in template quantities would result in a decrease in the PCR-generated signal.
The PCR was performed using 0.006 units/microliter of GoldStar polymerase (Eurogentec) and one micromolar of each primer.
The primers used, the size of the expected fragments and the PCR conditions are available on request from ogandril@cri.ens-lyon.fr. The identity of the ampli®ed RARb fragment was established by direct sequencing of the PCR product (not shown).
The sequence of the primers used are based on the sequences deposited in W3-accessible data banks except for the Rev (a and b) sequences that were generously provided by Vincent Laudet (Institut Pasteur, Lille). We veri®ed that larger size fragments arose from genomic DNA ampli®cation indicating that the PCR primers were separated by an intron on genomic DNA (data not shown).
Three dierent types of PCR programs were used:
(1) TouchDown PCR (TD; Don et al., 1991) : 5 min denaturation at 958C followed by a total of 46 cycles. Each cycle consists in 30 s denaturation at 958C, 30 s annealing and 45 s elongation at 758C. The ®rst two cycles were annealed at 728C, the following two at 708C, the following two at 688C, the following two at 668C, the following two at 648C, the following four at 628C, the following four at 608C, and ®nally 28 cycles at 558C. The reaction was ended by a 10 min elongation step at 728C.
(2) Stepdown PCR (SD; Hecker and Roux, 1996) ; this represents a simpli®ed derivation of the TouchDown protocol. It consists in: 4 min denaturation at 948C, 10 cycles (1 min denaturation at 948C, 1 min annealing at 708C and 1 min elongation at 728C); 30 cycles (1 min denaturation at 948C, 1 min annealing at 558C and 1 min elongation at 728C). The reaction was ended by a 10 min elongation step at 728C. (3) standard PCR: 4 min denaturation at 948C followed by 35 cycles of 1 min denaturation at 948C, 1 min annealing at AT (annealing temperature speci®ed in the right column; Table 1 ) and 1 min elongation at 728C. The reaction was ended by a 10 min elongation step at 728C. One tenth of the ampli®cation product was analysed on a 3% agarose gel (1% SeaKem; 2% NuSieve). Gels were photographed under u.v. light.
All of the PCR shown have been performed at least twice with identical results.
Growth measurement
Cell numbers were estimated after seeding 100 mg-aliquots of cells at 10 5 cells/ml in 96-wells plates in the presence of indicated concentrations of retinoids. Cells were grown for 48 h and their number was determined using the XTT test (Boehringer Mannheim) according to manufacturers instructions. Each point corresponds to the mean +/s.d. of at least two independent determinations performed in triplicates.
Dierentiation assay
T2ECs were induced to dierentiate by the addition in the liquid growth medium of either 0.5 U/ml erythropoietin (human recombinant; Boehringer Mannheim) and 10 ng/ml insulin (Epo/Ins) for 3 days or of 15% of Anemic Chicken Serum (ACS) for 6 days as indicated.
The ACS was prepared as follows: Day 1: adult chicken were injected intraperitoneally with 600 ml of a 3% solution of phenylhydrazine in PBS per kg of body weight; Day 2: intraperitoneal injections of 750 ml of a 3% solution of phenylhydrazine per kg; Day 3: chicken were put to diet; Day 4: the animal were sacri®ced and the blood was obtained by intracardiac puncture. The dilacerated clot was let overnight at room temperature; Day 5: the serum was obtained after centrifugation (4000 trs/mn for 10 min), sterile ®ltered and stored at 7208C.
The level of dierentiation was estimated by acidic benzidine staining: aliquotes of cells were mixed with one volume of acidic benzidine (20 ml of H 2 O 2 added extemporaneously to 1 ml of a benzidine solution at 2 mg/ml in a 3% acetic acid solution) and incubated in the dark for 5 mn. The percentage of benzidine-positive blue cells was counted on at least 100 cells per point. Statistical analysis were performed using a student's t-test.
